DEA Moves to Allow VA Research Program to Import Marijuana Extract and THC for Clinical Trials
The DEA authorization VA cannabis research marks a pivotal shift enabling clinical trials with standardized marijuana extracts. This federal move supports VA researchers in studying cannabis efficacy for veteran-specific conditions. It promises stronger…
Trump Signs Order to Fast-Track Psychedelic Research | Euronews – CED Clinic
The focus on psychedelic research acceleration aims to speed up evidence generation for psychiatric conditions. This policy shift may influence FDA approval timelines and clinical trial accessibility. It highlights emerging developments in psychedelic…
Joe Rogan Praises Trump’s Executive Order on Psychedelic Research
Psychedelic research funding is crucial for advancing clinical trials and expanding therapeutic options. Trump's executive order aims to accelerate this funding to improve treatment access. This policy shift could significantly impact clinical research…
Medical Cannabis for Orthopaedic Pain: Promising Signal, Weak Evidence Base
Medical cannabis orthopedic pain is a growing area of patient interest despite limited high-quality evidence. This review highlights promising signals for musculoskeletal conditions but notes weak study designs. Clinicians should consider cannabis as…
Cannabinoid Clinical Trials: Teen Cannabis Intervention Study
Adolescent cannabis use disorder intervention is critical due to neurodevelopmental risks during brain maturation. Clinical trials provide essential data on effective teen cannabis use disorder treatments. Evidence-based interventions remain limited but…
Trump Plans Psychedelic Executive Order (Newsletter: April 17, 2026)
The 2026 psychedelic drug policy developments could reshape access to psilocybin and MDMA treatments currently in FDA trials. These changes matter clinically for patients with PTSD and depression. Clinicians should monitor these developments closely for…
Cannabinoid Clinical Trials: EEG Sleep Insomnia RCT
This pilot trial studied the acute effects oral cannabinoids sleep insomnia in 20 patients. The combination of THC and CBD reduced total sleep time and altered EEG sleep patterns. These findings highlight the complexity of cannabinoid effects on sleep in…
IGC Pharma Nears Completion of Phase 2 CALMA Trial Enrollment
The phase 2 CALMA trial enrollment by IGC Pharma has reached 80%, marking significant progress in cannabis-derived therapeutic research. This trial aims to establish safety and efficacy data for a novel cannabis pharmaceutical candidate. Clinicians…
An Investigation of Cannabis and Mood Study for Class Project ($25 RAFFLE FOR …)
Student-led cannabis research projects often lack proper clinical research standards, impacting data validity. This mood study highlights challenges in informal cannabis research. Clinicians should be aware of these issues when discussing cannabis…
Medical Cannabis Market Growth and Clinical Research Outlook 2026-2033
The medical cannabis market growth 2026 is driven by intensified clinical research and development of pharmaceutical-grade products. Clinicians must stay informed about emerging evidence to guide patient care. This evolving landscape promises more…